AMNEAL PHARMACEUTICALS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $69.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $69.61M, a 95.49% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $78.00M, a 216.84% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $49.57M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $18.13M, a 54.22% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was $127.93M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$73.88M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$48.72M.
- AMNEAL PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$254.79M, a 1363.21% decline from fiscal 2021.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 2 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 4 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $69.61M 10-Q · filed 2026-08-06 | $147.61M 10-Q · filed 2026-08-06 | $197.19M derived: sum of 3 quarters · filed 2026-08-06 | $215.32M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $78.00M 10-Q · filed 2026-05-07 | $127.57M derived: sum of 2 quarters · filed 2026-05-07 | $145.71M derived: sum of 3 quarters · filed 2026-05-07 | $181.31M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $49.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $67.70M derived: sum of 2 quarters · filed 2026-02-27 | $103.31M derived: sum of 3 quarters · filed 2026-08-06 | $127.93M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $18.13M 10-Q · filed 2025-11-06 | $53.74M derived: sum of 2 quarters · filed 2026-08-06 | $78.36M 10-Q · filed 2025-11-06 | $57.62M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $35.61M 10-Q · filed 2026-08-06 | $60.23M 10-Q · filed 2026-08-06 | $39.49M derived: sum of 3 quarters · filed 2026-08-06 | $51.24M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $24.62M 10-Q · filed 2026-05-07 | $3.88M derived: sum of 2 quarters · filed 2026-05-07 | $15.63M derived: sum of 3 quarters · filed 2026-05-07 | $32.42M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$20.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$8.98M derived: sum of 2 quarters · filed 2026-02-27 | $7.80M derived: sum of 3 quarters · filed 2026-02-27 | -$73.88M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $11.76M 10-Q · filed 2025-11-06 | $28.54M derived: sum of 2 quarters · filed 2025-11-06 | -$53.13M 10-Q · filed 2025-11-06 | -$146.48M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-06-30 | $16.79M 10-Q · filed 2025-08-07 | -$64.89M 10-Q · filed 2025-08-07 | -$158.24M derived: sum of 3 quarters · filed 2026-02-27 | -$133.20M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-03-31 | -$81.68M 10-Q · filed 2025-05-07 | -$175.02M derived: sum of 2 quarters · filed 2026-02-27 | -$149.99M derived: sum of 3 quarters · filed 2026-02-27 | -$120.31M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2023-12-31 | -$93.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$68.31M derived: sum of 2 quarters · filed 2026-02-27 | -$38.63M derived: sum of 3 quarters · filed 2026-02-27 | -$48.72M 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $25.03M 10-Q · filed 2024-11-12 | $54.72M derived: sum of 2 quarters · filed 2024-11-12 | $44.62M 10-Q · filed 2024-11-12 | $38.76M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $29.68M 10-Q · filed 2024-08-09 | $19.59M 10-Q · filed 2024-08-09 | $13.73M derived: sum of 3 quarters · filed 2025-02-28 | $11.34M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | -$10.09M 10-Q · filed 2024-05-08 | -$15.95M derived: sum of 2 quarters · filed 2025-02-28 | -$18.34M derived: sum of 3 quarters · filed 2025-02-28 | -$258.42M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2022-12-31 | -$5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$8.25M derived: sum of 2 quarters · filed 2025-02-28 | -$248.33M derived: sum of 3 quarters · filed 2025-02-28 | -$254.79M 10-K · filed 2025-02-28 | ||
| 2022-09-30 | -$2.39M 10-Q · filed 2023-11-09 | -$242.47M derived: sum of 2 quarters · filed 2023-11-09 | -$248.93M 10-Q · filed 2023-11-09 | -$269.39M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | -$240.08M 10-Q · filed 2023-08-08 | -$246.54M 10-Q · filed 2023-08-08 | -$267.00M derived: sum of 3 quarters · filed 2024-03-14 | -$273.09M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | -$6.46M 10-Q · filed 2023-05-09 | -$26.92M derived: sum of 2 quarters · filed 2024-03-14 | -$33.01M derived: sum of 3 quarters · filed 2024-03-14 | -$835.00K derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2021-12-31 | -$20.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$26.55M derived: sum of 2 quarters · filed 2024-03-14 | $5.63M derived: sum of 3 quarters · filed 2024-03-14 | $20.17M 10-K · filed 2024-03-14 | ||
| 2021-09-30 | -$6.09M 10-Q · filed 2022-11-07 | $26.08M derived: sum of 2 quarters · filed 2022-11-07 | $40.63M 10-Q · filed 2022-11-07 | $33.67M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2021-06-30 | $32.18M 10-Q · filed 2022-08-08 | $46.72M 10-Q · filed 2022-08-08 | $39.76M derived: sum of 3 quarters · filed 2023-03-03 | $17.73M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2021-03-31 | $14.54M 10-Q · filed 2022-05-06 | $7.58M derived: sum of 2 quarters · filed 2023-03-03 | -$14.45M derived: sum of 3 quarters · filed 2023-03-03 | -$38.39M derived: sum of 4 quarters · filed 2023-03-03 | ||
| 2020-12-31 | -$6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$29.00M derived: sum of 2 quarters · filed 2023-03-03 | -$52.94M derived: sum of 3 quarters · filed 2023-03-03 | $68.58M 10-K · filed 2023-03-03 | ||
| 2020-09-30 | -$22.03M 10-Q · filed 2021-11-08 | -$45.98M derived: sum of 2 quarters · filed 2021-11-08 | $75.54M 10-Q · filed 2021-11-08 | $10.64M derived: sum of 4 quarters · filed 2021-11-08 | ||
| 2020-06-30 | -$23.94M 10-Q · filed 2021-08-09 | $97.57M 10-Q · filed 2021-08-09 | $32.67M derived: sum of 3 quarters · filed 2021-08-09 | -$330.72M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | $121.52M 10-Q · filed 2021-05-07 | $56.61M derived: sum of 2 quarters · filed 2021-05-07 | -$306.78M derived: sum of 3 quarters · filed 2021-05-07 | -$357.30M derived: sum of 4 quarters · filed 2021-05-07 | ||
| 2019-12-31 | -$64.90M 10-K · filed 2020-03-02 | -$428.30M derived: sum of 2 quarters · filed 2020-11-06 | -$478.82M derived: sum of 3 quarters · filed 2020-11-06 | -$603.57M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$363.39M 10-Q · filed 2020-11-06 | -$413.92M derived: sum of 2 quarters · filed 2020-11-06 | -$538.67M 10-Q · filed 2020-11-06 | -$559.00M derived: sum of 4 quarters · filed 2020-11-06 | ||
| 2019-06-30 | -$50.53M 10-Q · filed 2020-08-06 | -$175.28M 10-Q · filed 2020-08-06 | -$195.61M derived: sum of 3 quarters · filed 2020-08-06 | -$178.14M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | -$124.75M 10-Q · filed 2020-05-11 | -$145.08M derived: sum of 2 quarters · filed 2020-05-11 | -$127.62M derived: sum of 3 quarters · filed 2020-05-11 | -$377.71M derived: sum of 4 quarters · filed 2020-05-11 | ||
| 2018-12-31 | -$20.33M 10-K · filed 2020-03-02 | -$2.87M derived: sum of 2 quarters · filed 2020-03-02 | -$252.96M derived: sum of 3 quarters · filed 2020-03-02 | -$201.30M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $17.46M 10-K · filed 2020-03-02 | -$232.63M derived: sum of 2 quarters · filed 2020-03-02 | -$180.97M 10-Q · filed 2019-11-07 | -$118.78M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | -$49.73M 10-Q · filed 2019-08-05 | -$250.09M 10-K · filed 2020-03-02 | -$198.44M 10-Q · filed 2019-08-05 | -$136.24M derived: sum of 3 quarters · filed 2020-03-02 | -$109.12M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-05-03 | -$148.71M 10-K · filed 2019-03-01 | |||||
| 2018-03-31 | $51.65M 10-K · filed 2020-03-02 | $113.85M derived: sum of 2 quarters · filed 2020-03-02 | $140.97M derived: sum of 3 quarters · filed 2020-03-02 | $178.72M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2017-12-31 | $62.19M 10-K · filed 2019-03-01 | $89.32M derived: sum of 2 quarters · filed 2019-03-01 | $127.06M derived: sum of 3 quarters · filed 2019-03-01 | $169.32M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $27.12M 10-K · filed 2019-03-01 | $64.87M derived: sum of 2 quarters · filed 2019-03-01 | $107.13M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $37.75M 10-K · filed 2019-03-01 | $80.01M 10-Q · filed 2018-08-09 | ||||
| 2017-03-31 | $42.26M 10-K · filed 2019-03-01 | |||||
| 2016-12-31 | $209.43M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |